Summary

Persistence Market Research, a leading market research firm, has recently published an extensive analysis of the global market for Irritable Bowel Syndrome (IBS) treatments. This comprehensive report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers a detailed overview of the IBS treatment industry, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2033.

Key Insights:

• IBS Treatment Market Size (2024E): USD 3.9 Billion
• Projected Market Value (2033F): USD 8.1 Billion
• Global Market Growth Rate (CAGR 2024 to 2033): 8.4%

IBS Treatment Market - Report Scope:

Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. The treatment market for IBS includes a range of pharmaceuticals, dietary supplements, and lifestyle modification programs aimed at managing symptoms and improving patient quality of life. The market caters to hospitals, clinics, and homecare settings, offering a variety of treatment options, including antispasmodics, laxatives, fiber supplements, and probiotics.

Market Growth Drivers:

The global IBS treatment market is driven by several key factors, including growing awareness about IBS and its impact on quality of life. The rising prevalence of IBS, particularly in developed countries, fuels demand for effective treatment solutions. Technological advancements, such as novel pharmaceuticals and personalized medicine approaches, enhance treatment outcomes and reduce symptom severity, fostering market growth. Moreover, the adoption of telemedicine services and home-based treatment options opens new avenues for market players to reach a wider patient population.

Market Restraints:

Despite its promising growth, the IBS treatment market faces challenges related to regulatory compliance, reimbursement policies, and the high cost of certain therapies. Stringent regulations governing approval and marketing impose compliance burdens on manufacturers and healthcare providers, impacting market entry and operational costs. Limited reimbursement coverage and economic constraints in emerging economies further hinder market penetration. Addressing these barriers requires collaboration among industry stakeholders and policymakers to ensure access to affordable and safe IBS treatments.

Market Opportunities:

The IBS treatment market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. Integration of digital health technologies enhances patient access to treatments and improves outcomes. The expanding application of probiotics and microbiome-based therapies, along with novel drug delivery systems, broadens market scope and stimulates innovation. Strategic partnerships, R&D investments, and user-friendly, cost-effective solutions are crucial to capitalize on emerging opportunities and maintain market leadership.

Key Questions Answered in the Report:

• What factors drive global growth in the IBS treatment market?
• Which treatment types and applications lead IBS treatment adoption across healthcare settings?
• How do technological advancements reshape the competitive landscape?
• Who are the key players and their strategies for market relevance?
• What are emerging trends and future prospects in the global IBS treatment market?

Competitive Intelligence and Business Strategy:

Leading players like Takeda Pharmaceutical, Abbott Laboratories, and Allergan Plc focus on innovation, differentiation, and partnerships for competitive advantage. They invest in R&D for advanced solutions catering to diverse patient needs. Collaborations with healthcare providers and regulatory bodies aid market access and adoption. Emphasis on clinical research and patient education supports growth in this dynamic IBS treatment landscape.

Key Companies Profiled:

• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• Abbott Laboratories
• Novartis AG
• AstraZeneca PLC
• Ironwood Pharmaceuticals Inc. and Allergan Plc
• Bausch Health Companies Inc.
• GlaxoSmithKline, Plc.
• Lexicon Pharmaceuticals, Inc.
• Sucampo Pharmaceuticals, Inc.

Key Segments Covered in Irritable Bowel Syndrome Treatment Industry Research

By Product:
• Fiber Supplements
• Anti-Diarrheal
• Anticholinergic and Antispasmodic
• Antidepressant
• Antibiotics
• Alosetron
• Lubiprostone
• Linaclotide
• NHE3

By Indication:
• Irritable Bowel Syndrome with Constipation
• Irritable Bowel Syndrome with Diarrhoea
• Irritable Bowel Syndrome with alternating Constipation and Diarrhoea

By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies and Stores
• Hypermarkets and Supermarkets

By Region:
• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption Analysis
4.2. Key Regulations
4.3. PESTEL Analysis
4.4. Pipeline Assessment
4.5. Porter’s Analysis
4.6. Value Chain Analysis
4.7. Promotional Strategies, By Key Manufacturers
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Gastrointestinal Treatment Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase in R&D Spending
5.2.2. Growing Lifestyle Disease Prevalence
5.2.3. Cost of Drug
5.2.4. Adoption Rate of Treatment
5.2.5. Strategic Collaborations
5.2.6. Changes in Regulatory Policies
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Indication
6.1.3. By Distribution Channel
6.1.4. By Country
6.2. 2024 Market Scenario
7. Global Irritable Bowel Syndrome Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Product, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2024-2033
8.3.1. Fiber Supplements
8.3.2. Anti-Diarrheal
8.3.3. Anticholinergic and Antispasmodic
8.3.4. Antidepressant
8.3.5. Antibiotics
8.3.6. Alosetron
8.3.7. Lubiprostone
8.3.8. Linaclotide
8.3.9. NHE3
8.4. Market Attractiveness Analysis By Product
9. Global Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2024-2033
9.3.1. Irritable Bowel Syndrome with Constipation
9.3.2. Irritable Bowel Syndrome with Diarrhea
9.3.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
9.4. Market Attractiveness Analysis By Indication
10. Global Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Drug Stores
10.3.4. Online Pharmacies and Stores
10.3.5. Hypermarkets and Supermarkets
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Product
12.3.3. By Indication
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product
12.4.3. By Indication
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Key Players - Intensity Mapping
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Irritable Bowel Syndrome Treatment Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Product
12.8.1.2.2. By Indication
12.8.1.2.3. By Distribution Channel
12.8.2. Canada Irritable Bowel Syndrome Treatment Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Product
12.8.2.2.2. By Indication
12.8.2.2.3. By Distribution Channel
13. Latin America Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Product
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By Indication
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Players - Intensity Mapping
13.8. Country Level Analysis & Forecast
13.8.1. Mexico Irritable Bowel Syndrome Treatment Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product
13.8.1.2.2. By Indication
13.8.1.2.3. By Distribution Channel
13.8.2. Brazil Irritable Bowel Syndrome Treatment Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product
13.8.2.2.2. By Indication
13.8.2.2.3. By Distribution Channel
13.8.3. Argentina Irritable Bowel Syndrome Treatment Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Product
13.8.3.2.2. By Indication
13.8.3.2.3. By Distribution Channel
14. Europe Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Product
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Indication
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
14.8.1. Germany Irritable Bowel Syndrome Treatment Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product
14.8.1.2.2. By Indication
14.8.1.2.3. By Distribution Channel
14.8.2. Italy Irritable Bowel Syndrome Treatment Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product
14.8.2.2.2. By Indication
14.8.2.2.3. By Distribution Channel
14.8.3. France Irritable Bowel Syndrome Treatment Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product
14.8.3.2.2. By Indication
14.8.3.2.3. By Distribution Channel
14.8.4. U.K. Irritable Bowel Syndrome Treatment Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Product
14.8.4.2.2. By Indication
14.8.4.2.3. By Distribution Channel
14.8.5. Spain Irritable Bowel Syndrome Treatment Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Product
14.8.5.2.2. By Indication
14.8.5.2.3. By Distribution Channel
14.8.6. BENELUX Irritable Bowel Syndrome Treatment Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Product
14.8.6.2.2. By Indication
14.8.6.2.3. By Distribution Channel
14.8.7. Russia Irritable Bowel Syndrome Treatment Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Product
14.8.7.2.2. By Indication
14.8.7.2.3. By Distribution Channel
15. East Asia Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Product
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Indication
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
15.8.1. China Irritable Bowel Syndrome Treatment Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Indication
15.8.1.2.3. By Distribution Channel
15.8.2. Japan Irritable Bowel Syndrome Treatment Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Indication
15.8.2.2.3. By Distribution Channel
15.8.3. South Korea Irritable Bowel Syndrome Treatment Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product
15.8.3.2.2. By Indication
15.8.3.2.3. By Distribution Channel
16. South Asia Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Product
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Indication
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
16.8.1. India Irritable Bowel Syndrome Treatment Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Indication
16.8.1.2.3. By Distribution Channel
16.8.2. Indonesia Irritable Bowel Syndrome Treatment Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Indication
16.8.2.2.3. By Distribution Channel
16.8.3. Malaysia Irritable Bowel Syndrome Treatment Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Indication
16.8.3.2.3. By Distribution Channel
16.8.4. Thailand Irritable Bowel Syndrome Treatment Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Product
16.8.4.2.2. By Indication
16.8.4.2.3. By Distribution Channel
17. Oceania Irritable Bowel Syndrome Treatment Market 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Product
17.3.3. By Indication
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Indication
17.4.4. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
17.8.1. Australia Irritable Bowel Syndrome Treatment Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Indication
17.8.1.2.3. By Distribution Channel
17.8.2. New Zealand Irritable Bowel Syndrome Treatment Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Indication
17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Turkey
18.3.1.3. North Africa
18.3.1.4. South Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Product
18.3.3. By Indication
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Indication
18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Key Players - Intensity Mapping
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Irritable Bowel Syndrome Treatment Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Indication
18.8.1.2.3. By Distribution Channel
18.8.2. Turkey Irritable Bowel Syndrome Treatment Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Indication
18.8.2.2.3. By Distribution Channel
18.8.3. South Africa Irritable Bowel Syndrome Treatment Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Product
18.8.3.2.2. By Indication
18.8.3.2.3. By Distribution Channel
18.8.4. North Africa Irritable Bowel Syndrome Treatment Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Product
18.8.4.2.2. By Indication
18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive
20.2.1. Pfizer, Inc.
20.2.1.1. Overview
20.2.1.2. Product Portfolio
20.2.1.3. Sales Footprint
20.2.1.4. Key Financials
20.2.1.5. SWOT Analysis
20.2.1.6. Strategy Overview
20.2.1.6.1. Marketing Strategy
20.2.1.6.2. Product Strategy
20.2.1.6.3. Channel Strategy
20.2.2. Takeda Pharmaceutical Company Limited
20.2.2.1. Overview
20.2.2.2. Product Portfolio
20.2.2.3. Sales Footprint
20.2.2.4. Key Financials
20.2.2.5. SWOT Analysis
20.2.2.6. Strategy Overview
20.2.2.6.1. Marketing Strategy
20.2.2.6.2. Product Strategy
20.2.2.6.3. Channel Strategy
20.2.3. Abbott Laboratories
20.2.3.1. Overview
20.2.3.2. Product Portfolio
20.2.3.3. Sales Footprint
20.2.3.4. Key Financials
20.2.3.5. SWOT Analysis
20.2.3.6. Strategy Overview
20.2.3.6.1. Marketing Strategy
20.2.3.6.2. Product Strategy
20.2.3.6.3. Channel Strategy
20.2.4. Novartis AG
20.2.4.1. Overview
20.2.4.2. Product Portfolio
20.2.4.3. Sales Footprint
20.2.4.4. Key Financials
20.2.4.5. SWOT Analysis
20.2.4.6. Strategy Overview
20.2.4.6.1. Marketing Strategy
20.2.4.6.2. Product Strategy
20.2.4.6.3. Channel Strategy
20.2.5. AstraZeneca PLC
20.2.5.1. Overview
20.2.5.2. Product Portfolio
20.2.5.3. Sales Footprint
20.2.5.4. Key Financials
20.2.5.5. SWOT Analysis
20.2.5.6. Strategy Overview
20.2.5.6.1. Marketing Strategy
20.2.5.6.2. Product Strategy
20.2.5.6.3. Channel Strategy
20.2.6. Ironwood Pharmaceuticals Inc. and Allergan Plc
20.2.6.1. Overview
20.2.6.2. Product Portfolio
20.2.6.3. Sales Footprint
20.2.6.4. Key Financials
20.2.6.5. SWOT Analysis
20.2.6.6. Strategy Overview
20.2.6.6.1. Marketing Strategy
20.2.6.6.2. Product Strategy
20.2.6.6.3. Channel Strategy
20.2.7. Bausch Health Companies Inc.
20.2.7.1. Overview
20.2.7.2. Product Portfolio
20.2.7.3. Sales Footprint
20.2.7.4. Key Financials
20.2.7.5. SWOT Analysis
20.2.7.6. Strategy Overview
20.2.7.6.1. Marketing Strategy
20.2.7.6.2. Product Strategy
20.2.7.6.3. Channel Strategy
20.2.8. GlaxoSmithKline, Plc.
20.2.8.1. Overview
20.2.8.2. Product Portfolio
20.2.8.3. Sales Footprint
20.2.8.4. Key Financials
20.2.8.5. SWOT Analysis
20.2.8.6. Strategy Overview
20.2.8.6.1. Marketing Strategy
20.2.8.6.2. Product Strategy
20.2.8.6.3. Channel Strategy
20.2.9. Lexicon Pharmaceuticals, Inc.
20.2.9.1. Overview
20.2.9.2. Product Portfolio
20.2.9.3. Sales Footprint
20.2.9.4. Key Financials
20.2.9.5. SWOT Analysis
20.2.9.6. Strategy Overview
20.2.9.6.1. Marketing Strategy
20.2.9.6.2. Product Strategy
20.2.9.6.3. Channel Strategy
20.2.10. Sucampo Pharmaceuticals, Inc.
20.2.10.1. Overview
20.2.10.2. Product Portfolio
20.2.10.3. Sales Footprint
20.2.10.4. Key Financials
20.2.10.5. SWOT Analysis
20.2.10.6. Strategy Overview
20.2.10.6.1. Marketing Strategy
20.2.10.6.2. Product Strategy
20.2.10.6.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology